Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Gout
Interventions
DRUG

placebo

administered daily for 21 days

DRUG

BCX4208

Administered daily for 21 days.

Trial Locations (24)

16635

Altoona Center for Clinical Research, Duncansville

21702

Arthritis & Osteoporosis Center of Maryland, Frederick

27609

Triangle Medical Research Associates, Raleigh

29732

Carolinas Center for Rheumatology & Arthritis, Rock Hill

32720

Avail Clinical Research, DeLand

34102

Anchor Research Center, Naples

38654

Olive Branch Family Medical Center, Olive Branch

40504

Kentucky Medical Research Center, Lexington

45417

STAT Research, Dayton

57702

Health Concepts, Rapid City

59715

Bozeman Urgent Care Center, Bozeman

63117

Medex Healthcare Research, St Louis

68134

Heartland Clinical Research, Omaha

73112

Lynn Health Science Institute, Oklahoma City

75235

Renaissance Clinical Research, Dallas

83704

Selah Medical Center, Boise

85251

Radiant Research, Inc., Scottsdale

85704

Catalina Pointe Clinical Research, Tucson

87106

New Mexico Clinical Research & Osteoporosis Center, Albuquerque

89502

Arthritis Center of Reno, Reno

92108

San Diego Arthritis Medical Clinic, San Diego

92618

Irvine Center for Clinical Research, Irvine

96814

East-West Medical Research Institute, Honolulu

98004

Northwest Clinical Research Center, Bellevue

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY